S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1

Schlüsselwörter

Pankreaskarzinom - S3 Leitlinie Kurzversion - duktales Adenokarzinom des Pankreas - evidenzbasierte Medizin

Publikationsverlauf

Eingereicht: 03. Juni 2024

Angenommen: 04. Juni 2024

Artikel online veröffentlicht:
10. Oktober 2024

• Literatur

• 1 Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V., Zentrum für Krebsregisterdaten am Robert-Koch-Institut. Krebs in Deutschland 2019/2020. Gesundheitsberichterstattung des Bundes. 2023 https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_2023.pdf?__blob=publicationFile
• 2 Morze J, Danielewicz A, Przybylowicz K. et al. An updated systematic review and meta-analysis on adherence to mediterranean diet and risk of cancer. European Journal of Nutrition 2021; 60: 1561-1586 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987633/pdf/394_2020_Article_2346.pdf
• 3 Grosso G, Bella F, Godos J. et al. Possible role of diet in cancer: Systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk. Nutrition Reviews 2017; 75: 405-419 https://pubmed.ncbi.nlm.nih.gov/28969358/
• 4 Gao Y, Ma Y, Yu M. et al. Poultry and Fish Intake and Pancreatic Cancer Risk: A Systematic Review and Meta-Analysis. Nutrition & Cancer 2021; 1-13
• 5 Gao Y, Ma Y, Yu M. et al. Poultry and Fish Intake and Pancreatic Cancer Risk: A Systematic Review and Meta-Analysis. Nutr Cancer 2022; 74 (01) 55-67 https://pubmed.ncbi.nlm.nih.gov/33432844/
• 6 Zhao Z, Yin Z, Pu Z. et al. Association Between Consumption of Red and Processed Meat and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2017; 15: 486-493.e10 https://www.cghjournal.org/article/S1542-3565(16)30854-0/pdf
• 7 Mossine VV, Mawhinney TP, Giovannucci EL. Dried Fruit Intake and Cancer: A Systematic Review of Observational Studies. Advances in nutrition (Bethesda, Md.) 2020; 11: 237-250 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442373/pdf/nmz085.pdf
• 8 Zhao Z, Yu P, Feng X. et al. No associations between fruit and vegetable consumption and pancreatic cancer risk: A meta-analysis of prospective studies. Oncotarget 2018; 9: 32250-32261 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114958/
• 9 Wu QJ, Wu L, Zheng LQ. et al. Consumption of fruit and vegetables reduces risk of pancreatic cancer: Evidence from epidemiological studies. European Journal of Cancer Prevention 2016; 25: 196-205 https://pubmed.ncbi.nlm.nih.gov/26075658/
• 10 Darooghegi MofradM, Mozaffari H, Askari MR. et al. Potato Consumption and Risk of Site-Specific Cancers in Adults: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies. Advances in Nutrition 2021; 16: 16 https://academic.oup.com/advances/article-abstract/12/5/1705/6228237?redirectedFrom=fulltext
• 11 Mills PK, Beeson WL, Abbey DE. et al. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer 1988; 61: 2578-2585 https://pubmed.ncbi.nlm.nih.gov/3365678/
• 12 Zhang D, Dai C, Zhou L. et al. Meta-analysis of the association between nut consumption and the risks of cancer incidence and cancer-specific mortality. Aging 2020; 12: 10772-10794 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346045/pdf/aging-12-103292.pdf
• 13 Gaesser GA. Whole grains, refined grains, and cancer risk: A systematic review of meta-analyses of observational studies. Nutrients 2020; 12: 1-23 https://www.mdpi.com/2072-6643/12/12/3756/pdfhttps://mdpi-res.com/d_attachment/nutrients/nutrients-12-03756/article_deploy/nutrients-12-03756.pdf
• 14 McRae MP. The Benefits of Dietary Fiber Intake on Reducing the Risk of Cancer: An Umbrella Review of Meta-analyses. Journal of Chiropractic Medicine 2018; 17: 90-96 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112064/pdf/main.pdf
• 15 Llaha F, Gil-Lespinard M, Unal P. et al. Consumption of sweet beverages and cancer risk A systematic review and meta-analysis of observational studies. Nutrients 2021; 13: 1-35 https://www.mdpi.com/2072-6643/13/2/516/pdf
• 16 Milajerdi A, Larijani B, Esmaillzadeh A. Sweetened Beverages Consumption and Pancreatic Cancer: A Meta-Analysis. Nutrition & Cancer 2019; 71: 375-384 https://www.tandfonline.com/doi/full/10.1080/01635581.2019.1578390
• 17 Ghadirian P, Baillargeon J, Simard A. et al. Food habits and pancreatic cancer: a case-control study of the Francophone community in Montreal, Canada. Cancer Epidemiol Biomarkers Prev 1995; 4: 895-899 https://pubmed.ncbi.nlm.nih.gov/8634663/
• 18 Michaud DS, Liu S, Giovannucci E. et al. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002; 94: 1293-1300 https://pubmed.ncbi.nlm.nih.gov/12208894/
• 19 Silvera SA, Rohan TE, Jain M. et al. Glycemic index, glycemic load, and pancreatic cancer risk (Canada). Cancer Causes Control 2005; 16: 431-436 https://pubmed.ncbi.nlm.nih.gov/15953985/
• 20 Chen J, Jiang W, Shao L. et al. Association between intake of antioxidants and pancreatic cancer risk: a meta-analysis. International journal of food sciences and nutrition 2016; 67: 744-753 https://www.tandfonline.com/doi/full/10.1080/09637486.2016.1197892
• 21 Huang X, Gao Y, Zhi X. et al. Association between vitamin A, retinol and carotenoid intake and pancreatic cancer risk: Evidence from epidemiologic studies. Scientific Reports 2016; 6: 38936 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5150257/pdf/srep38936.pdf
• 22 Liu Y, Wang X, Sun X. et al. Vitamin intake and pancreatic cancer risk reduction: A meta-analysis of observational studies. Medicine 2018; 97: e0114 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895396/pdf/medi-97-e0114.pdf
• 23 Zhang T, Chen H, Qin S. et al. The association between dietary vitamin A intake and pancreatic cancer risk: a meta-analysis of 11 studies. Bioscience Reports 2016; 36: 12 https://pubmed.ncbi.nlm.nih.gov/27756825/
• 24 Xie L, Mo M, Jia HX. et al. Association between dietary nitrate and nitrite intake and sitespecific cancer risk: Evidence from observational studies. Oncotarget 2016; 7: 56915-56932 http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=10917&path%5B%5D=34570https://www.oncotarget.com/article/10917/pdf/
• 25 Fu H, Zeng J, Liu C. et al. Folate Intake and Risk of Pancreatic Cancer: A Systematic Review and Updated Meta-Analysis of Epidemiological Studies. Digestive Diseases and Sciences 2021; 66: 2368-2379 http://www.wkap.nl/journalhome.htm/0163-2116
• 26 Liu W, Zhou H, Zhu Y. et al. Associations between dietary folate intake and risks of esophageal, gastric and pancreatic cancers: An overall and dose-response meta-analysis. Oncotarget 2017; 8: 86828-86842 http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=18775&path%5B%5D=60299https://www.oncotarget.com/article/18775/pdf/
• 27 Wei DH, Mao QQ. Vitamin B6, vitamin B12 and methionine and risk of pancreatic cancer: a meta-analysis. Nutrition Journal 2020; 19: 111 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534168/pdf/12937_2020_Article_628.pdf
• 28 Peng YF, Han MM, Huang R. et al. Vitamin B6 Intake and Pancreatic Carcinoma Risk: A Meta-Analysis. Nutrition and Cancer 2019; 71: 1061-1066 https://www.tandfonline.com/doi/full/10.1080/01635581.2019.1598562
• 29 Mocellin S, Briarava M, Pilati P. Vitamin B6 and cancer risk: A field synopsis and meta-analysis. Journal of the National Cancer Institute 2017; 109: 1-9 https://pubmed.ncbi.nlm.nih.gov/28376200/
• 30 Zhang X, Huang XZ, Chen WJ. et al. Plasma 25-hydroxyvitamin D levels, vitamin D intake, and pancreatic cancer risk or mortality: a meta-analysis. Oncotarget 2017; 8: 64395-64406 https://www.oncotarget.com/article/18888/pdf/
• 31 Li L, Gai X. The association between dietary zinc intake and risk of pancreatic cancer: a meta-analysis. Bioscience Reports 2017; 37: 30 https://pubmed.ncbi.nlm.nih.gov/28428431/
• 32 Abbasalizad FarhangiM, Vajdi M. Dietary Total Antioxidant Capacity (TAC) Significantly Reduces the Risk of Site-Specific Cancers: An Updated Systematic Review and Meta-Analysis. Nutrition and Cancer 2021; 73: 721-739 https://www.tandfonline.com/doi/full/10.1080/01635581.2020.1771385
• 33 Guo Z, Hong Y, Cheng Y. Dietary inflammatory index and pancreatic cancer risk: a systematic review and dose-response meta-analysis. Public Health Nutrition 2021; 1-9 https://www.cambridge.org/core/journals/public-health-nutrition/article/abs/dietary-inflammatory-index-and-pancreatic-cancer-risk-a-systematic-review-and-doseresponse-metaanalysis/F09C050021A2B14072043B74E84D2FFD
• 34 Wang Y, Gou Y, Jin W. et al. Association between alcohol intake and the risk of pancreatic cancer: a dose-response meta-analysis of cohort studies. BMC Cancer 2016; 16: 212 https://pubmed.ncbi.nlm.nih.gov/26968702/
• 35 Lugo A, Peveri G, Bosetti C. et al. Strong excess risk of pancreatic cancer for low frequency and duration of cigarette smoking: A comprehensive review and meta-analysis. Eur J Cancer 2018; 104: 117-126 https://pubmed.ncbi.nlm.nih.gov/30347287/
• 36 Gupta S, Gupta R, Sinha D. et al. Relationship between type of smokeless tobacco & risk of cancer: A systematic review. Indian J Med Res 2018; 148 (01) 56-76 https://pubmed.ncbi.nlm.nih.gov/30264755/
• 37 Ordóñez-Mena J, Schöttker B, Mons U. et al. Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium. BMC Med 2016; 14: 62 https://pubmed.ncbi.nlm.nih.gov/27044418/
• 38 Lee PN, Thornton AJ, Hamling JS. Epidemiological evidence on environmental tobacco smoke and cancers other than lung or breast. Regulatory Toxicology & Pharmacology 2016; 80: 134-163
• 39 Li TD, Yang HW, Wang P. et al. Coffee consumption and risk of pancreatic cancer: a systematic review and dose-response meta-analysis. International journal of food sciences and nutrition 2019; 70: 519-529 https://www.tandfonline.com/doi/full/10.1080/09637486.2018.1551337
• 40 Ran HQ, Wang JZ, Sun CQ. Coffee consumption and pancreatic cancer risk: An update meta-analysis of cohort studies. Pakistan Journal of Medical Sciences 2016; 32: 253-259 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794517/pdf/PJMS-32-253.pdf
• 41 Alguacil J, Pollan M, Gustavsson P. Occupations with increased risk of pancreatic cancer in the Swedish population. Occup Environ Med 2003; 60: 570-576 https://pubmed.ncbi.nlm.nih.gov/12883017/
• 42 Alguacil J, Porta M, Benavides FG. et al. Occupation and pancreatic cancer in Spain: a case-control study based on job titles PANKRAS II Study Group. Int J Epidemiol 2000; 29: 1004-1013 https://pubmed.ncbi.nlm.nih.gov/11101541/
• 43 Laakkonen A, Kauppinen T, Pukkala E. Cancer risk among Finnish food industry workers. Int J Cancer 2006; 118: 2567-2571 https://pubmed.ncbi.nlm.nih.gov/16380992/
• 44 Fryzek JP, Garabrant DH, Harlow SD. et al. A case-control study of self-reported exposures to pesticides and pancreas cancer in southeastern Michigan. Int J Cancer 1997; 72: 62-67 https://pubmed.ncbi.nlm.nih.gov/9212224/
• 45 Ji BT, Silverman DT, Stewart PA. et al. Occupational exposure to pesticides and pancreatic cancer. Am J Ind Med 2001; 39: 92-99 https://pubmed.ncbi.nlm.nih.gov/11148019/
• 46 Ojajarvi IA, Partanen TJ, Ahlbom A. et al. Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med 2000; 57: 316-324 https://pubmed.ncbi.nlm.nih.gov/10769297/
• 47 Ojajarvi A, Partanen T, Ahlbom A. et al. Risk of pancreatic cancer in workers exposed to chlorinated hydrocarbon solvents and related compounds: a meta-analysis. Am J Epidemiol 2001; 153: 841-850 https://pubmed.ncbi.nlm.nih.gov/11323314/
• 48 Weiderpass E, Vainio H, Kauppinen T. et al. Occupational exposures and gastrointestinal cancers among Finnish women. J Occup Environ Med 2003; 45: 305-315 https://pubmed.ncbi.nlm.nih.gov/12661188/
• 49 Yassi A, Tate RB, Routledge M. Cancer incidence and mortality in workers employed at a transformer manufacturing plant: update to a cohort study. Am J Ind Med 2003; 44: 58-62 https://pubmed.ncbi.nlm.nih.gov/12822136/
• 50 Ji J, Hemminki K. Socioeconomic and occupational risk factors for pancreatic cancer: a cohort study in Sweden. J Occup Environ Med 2006; 48: 283-288 https://pubmed.ncbi.nlm.nih.gov/16531832/
• 51 Xie F, You Y, Huang J. et al. Association between physical activity and digestive-system cancer: An updated systematic review and meta-analysis. J Sport Health Sci 2021; 10 (01) 4-13
• 52 Silveira EA, Kliemann N, Noll M. et al. Visceral obesity and incident cancer and cardiovascular disease: An integrative review of the epidemiological evidence. Obesity Reviews 2021; 22 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.13088?download=true
• 53 Hidayat K, Du X, Shi BM. Body fatness at a young age and risks of eight types of cancer: systematic review and meta-analysis of observational studies. Obesity Reviews 2018; 19: 1385-1394 http://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/obr.12705?download=true
• 54 Seo MS, Yeo J, Hwang IC. et al. Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis. Clinical Rheumatology 2019; 38: 3109-3116 https://link.springer.com/content/pdf/10.1007/s10067-019-04660-9.pdf
• 55 Zhang JJ, Jia JP, Shao Q. et al. Diabetes mellitus and risk of pancreatic cancer in China: A meta-analysis based on 26 case-control studies. Primary Care Diabetes 2019; 13: 276-282 https://www.primary-care-diabetes.com/article/S1751-9918(18)30091-3/fulltext
• 56 Aune D, Sen A, Norat T. et al. Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies. Scientific reports 2021; 11: 10646 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137938/pdf/41598_2021_Article_90175.pdf
• 57 Fan Y, Hu J, Feng B. et al. Increased risk of pancreatic cancer related to gallstones and cholecystectomy a systematic review and meta-analysis. Pancreas 2016; 45: 503-509 http://journals.lww.com/pancreasjournal
• 58 Trafford AM, Parisi R, Kontopantelis E. et al. Association of Psoriasis with the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis. JAMA Dermatology 2019; 155: 1390-1403 https://jamanetwork.com/journals/jamadermatology/articlepdf/2753127/jamadermatology_trafford_2019_oi_190054.pdf
• 59 Arafa A, Eshak ES, Abdel RahmanTA. et al. Hepatitis C virus infection and risk of pancreatic cancer: A meta-analysis. Cancer Epidemiology 2020; 65: 101691
• 60 Leung CY, Huang HL, Rahman MM. et al. Cancer incidence attributable to tuberculosis in 2015: global, regional, and national estimates. BMC Cancer 2020; 20: 412 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218646/pdf/12885_2020_Article_6891.pdf
• 61 Liu H, Chen YT, Wang R. et al. Helicobacter pylori infection, atrophic gastritis, and pancreatic cancer risk: A meta-analysis of prospective epidemiologic studies. Medicine 2017; 96: e7811 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571714/pdf/medi-96-e7811.pdf
• 62 Liu SS, Ma XF, Zhao J. et al. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. Lipids in Health & Disease 2020; 19: 118 https://lipidworld.biomedcentral.com/track/pdf/10.1186/s12944-020-01288-6.pdf
• 63 Liu X, Zhang ZH, Jiang F. Hepatitis B virus infection increases the risk of pancreatic cancer: a meta-analysis. Scandinavian Journal of Gastroenterology 2021; 56: 252-258 https://www.tandfonline.com/doi/full/10.1080/00365521.2020.1868568
• 64 Maisonneuve P, Amar S, Lowenfels AB. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology 2017; 28: 985-995 https://www.annalsofoncology.org/article/S0923-7534(19)32001-0/pdf
• 65 Michaud DS, Fu Z, Shi J. et al. Periodontal disease, tooth loss, and cancer risk. Epidemiologic Reviews 2017; 39: 49-58 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868279/pdf/mxx006.pdf
• 66 Shi J, Leng W, Zhao L. et al. Tooth loss and cancer risk: a dose-response meta analysis of prospective cohort studies. Oncotarget 2018; 9: 15090-15100 https://www.oncotarget.com/article/23850/pdf/
• 67 Wang L, Bierbrier R, Drucker AM. et al. Noncutaneous and Cutaneous Cancer Risk in Patients With Atopic Dermatitis: A Systematic Review and Meta-analysis. JAMA Dermatology 2020; 156: 158-171 https://jamanetwork.com/journals/jamadermatology/articlepdf/2757273/jamadermatology_wang_2019_oi_190064.pdf
• 68 Pang Y, Holmes MV, Kartsonaki C. et al. Young adulthood and adulthood adiposity in relation to incidence of pancreatic cancer: a prospective study of 05 million Chinese adults and a meta-analysis. Journal of epidemiology and community health 2017; 71: 1059-1067 https://jech.bmj.com/content/jech/71/11/1059.full.pdf
• 69 Wang J, Yang DL, Chen ZZ. et al. Associations of body mass index with cancer incidence among populations, genders, and menopausal status: A systematic review and meta-analysis. Cancer Epidemiology 2016; 42: 1-8 http://www.elsevier.com
• 70 Tan J, You Y, Guo F. et al. Association of elevated risk of pancreatic cancer in diabetic patients: A systematic review and meta-analysis. Oncology Letters 2017; 13: 1247-1255 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403376/pdf/ol-13-03-1247.pdf
• 71 Sona MF, Myung SK, Park K. et al. Type 1 diabetes mellitus and risk of cancer: A meta-analysis of observational studies. Japanese Journal of Clinical Oncology 2018; 48: 426-433 https://pubmed.ncbi.nlm.nih.gov/29635473/
• 72 Fang HJ, Shan SB, Zhou YH. et al. Diabetes mellitus and the risk of gastrointestinal cancer in women compared with men: a meta-analysis of cohort studies. BMC Cancer 2018; 18: 422 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902961/pdf/12885_2018_Article_4351.pdf
• 73 Soltani S, Abdollahi S, Aune D. et al. Body mass index and cancer risk in patients with type 2 diabetes: a dose-response meta-analysis of cohort studies. Scientific reports 2021; 11: 2479 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844243/pdf/41598_2021_Article_81671.pdf
• 74 Pergolini I, Schorn S, Jager C. et al. Diabetes mellitus in intraductal papillary mucinous neoplasms: A systematic review and meta-analysis. Surgery 2021; 169: 411-418 https://www.surgjournal.com/article/S0039-6060(20)30448-7/fulltext
• 75 Wang Y, Yan P, Fu T. et al. The association between gestational diabetes mellitus and cancer in women: A systematic review and meta-analysis of observational studies. Diabetes and Metabolism 2020; 46: 461-471 http://www.elsevier.com/wps/find/journaldescription.cws_home/709654/description#description
• 76 Yamada A, Komaki Y, Komaki F. et al. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. The Lancet Oncology 2018; 19: 758-767 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30188-8/fulltext
• 77 Guo Y, Liu W, Wu J. Helicobacter pylori infection and pancreatic cancer risk: A meta-Analysis. Journal of Cancer Research and Therapeutics 2016; 12: C229-C232 https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2016;volume=12;issue=8;spage=229;epage=232;aulast=Guo
• 78 Zhang Y, Sun C, Song EJ. et al. Is periodontitis a risk indicator for gastrointestinal cancers? A meta-analysis of cohort studies. Journal of Clinical Periodontology 2020; 47: 134-147 https://onlinelibrary.wiley.com/doi/10.1111/jcpe.13217
• 79 Heydari K, Rismantab S, Alizadeh-Navaei R. et al. Risk of secondary malignancies in patients with ovarian cancer: A systematic review and meta-analysis. European Journal of Gynaecological Oncology 2021; 42: 234-243 https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.02.2238
• 80 Wang Y, Lan GB, Peng FH. et al. Cancer risks in recipients of renal transplants: a meta-analysis of cohort studies. Oncotarget 2018; 9: 15375-15385 https://www.oncotarget.com/article/23841/pdf/
• 81 Lowenfels AB, Maisonneuve P, DiMagno EP. et al. Hereditary pancreatitis and the risk of pancreatic cancer International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89: 442-446 https://pubmed.ncbi.nlm.nih.gov/9091646/
• 82 Howes N, Lerch MM, Greenhalf W. et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004; 2: 252-261 https://pubmed.ncbi.nlm.nih.gov/15017610/
• 83 Klein AP, Brune KA, Petersen GM. et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64: 2634-2638 https://pubmed.ncbi.nlm.nih.gov/15059921/
• 84 Bartsch DK, Slater EP, Carrato A. et al. Refinement of screening for familial pancreatic cancer. Gut 2016; 65: 1314-1321 https://www.ncbi.nlm.nih.gov/pubmed/27222532
• 85 Goggins M, Overbeek KA, Brand R. et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69: 7-17 https://www.ncbi.nlm.nih.gov/pubmed/31672839
• 86 Stoffel EM, McKernin SE, Brand R. et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. Journal of Clinical Oncology 2019; 37: 153-164 https://pubmed.ncbi.nlm.nih.gov/30589608/
• 87 Bjelakovic G, Nikolova D, Simonetti RG. et al. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004; 364: 1219-1228 https://pubmed.ncbi.nlm.nih.gov/15464182/
• 88 Coogan PF, Rosenberg L, Palmer JR. et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000; 9: 119-123 https://pubmed.ncbi.nlm.nih.gov/10667472/
• 89 Harris RE, Beebe-Donk J, Doss H. et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13: 559-583 https://pubmed.ncbi.nlm.nih.gov/15756426/
• 90 Jacobs EJ, Connell CJ, Rodriguez C. et al. Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 2004; 96: 524-528 https://pubmed.ncbi.nlm.nih.gov/15069114/
• 91 rBjornsson E, Ismael S, Nejdet S. et al. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003; 38: 86-94 https://pubmed.ncbi.nlm.nih.gov/12608470/
• 92 Reisman Y, Gips CH, Lavelle SM. et al. Clinical presentation of (subclinical) jaundice--the Euricterus project in The Netherlands United Dutch Hospitals and Euricterus Project Management Group. Hepatogastroenterology 1996; 43: 1190-1195 https://pubmed.ncbi.nlm.nih.gov/8908550/
• 93 Watanabe I, Sasaki S, Konishi M. et al. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas 2004; 28: 160-165 https://pubmed.ncbi.nlm.nih.gov/15028948/
• 94 Mujica VR, Barkin JS, Go VL. Acute pancreatitis secondary to pancreatic carcinoma Study Group Participants. Pancreas 2000; 21: 329-332 https://pubmed.ncbi.nlm.nih.gov/11075985/
• 95 Balthazar EJ. Pancreatitis associated with pancreatic carcinoma Preoperative diagnosis: role of CT imaging in detection and evaluation. Pancreatology 2005; 5: 330-344 https://pubmed.ncbi.nlm.nih.gov/16015017/
• 96 Adamek HE, Albert J, Breer H. et al. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 2000; 356: 190-193 https://pubmed.ncbi.nlm.nih.gov/10963196/
• 97 Hanninen EL, Ricke J, Amthauer H. et al. Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and value of additional T2- and T1-weighted sequences for the assessment of suspected pancreatic cancer. Acta Radiol 2005; 46: 117-125 https://pubmed.ncbi.nlm.nih.gov/15902884/
• 98 Nazli O, Bozdag AD, Tansug T. et al. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 2000; 47: 1750-1752 https://pubmed.ncbi.nlm.nih.gov/11149048/
• 99 Ritts RE, Nagorney DM, Jacobsen DJ. et al. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994; 9: 707-716 https://pubmed.ncbi.nlm.nih.gov/7846013/
• 100 Tessler DA, Catanzaro A, Velanovich V. et al. Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. Am J Surg 2006; 191: 191-197 https://pubmed.ncbi.nlm.nih.gov/16442944/
• 101 Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9. Pancreas 1994; 9: 731-734 https://pubmed.ncbi.nlm.nih.gov/7846016/
• 102 Varadarajulu S, Wallace MB. Applications of endoscopic ultrasonography in pancreatic cancer. Cancer Control 2004; 11: 15-22 https://pubmed.ncbi.nlm.nih.gov/14749619/
• 103 Agarwal B, Abu-Hamda E, Molke KL. et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 2004; 99: 844-850 https://pubmed.ncbi.nlm.nih.gov/15128348/
• 104 Klapman JB, Chang KJ, Lee JG. et al. Negative predictive value of endoscopic ultrasound in a large series of patients with a clinical suspicion of pancreatic cancer. Am J Gastroenterol 2005; 100: 2658-2661 https://pubmed.ncbi.nlm.nih.gov/16393216/
• 105 David O, Green L, Reddy V. et al. Pancreatic masses: a multi-institutional study of 364 fine-needle aspiration biopsies with histopathologic correlation. Diagn Cytopathol 1998; 19: 423-427 https://www.ncbi.nlm.nih.gov/pubmed/9839131
• 106 Bipat S, Phoa SS, van Delden OM. et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005; 29: 438-445 https://www.ncbi.nlm.nih.gov/pubmed/16012297
• 107 James PD, Meng ZW, Zhang M. et al. The incremental benefit of EUS for identifying unresectable disease among adults with pancreatic adenocarcinoma: A meta-analysis. PLoS One 2017; 12: e0173687 https://pubmed.ncbi.nlm.nih.gov/28319148/
• 108 Krishna S, Rao B, Ugbarugba E. et al. Diagnostic performance of endoscopic ultrasound for detection of pancreatic malignancy following an indeterminate multidetector CT scan: a systemic review and meta-analysis. Surgical Endoscopy 2017; 31: 4558-4567 https://pubmed.ncbi.nlm.nih.gov/28378082/
• 109 Chew C, O'Dwyer PJ. The value of liver magnetic resonance imaging in patients with findings of resectable pancreatic cancer on computed tomography. Singapore Med J 2016; 57: 334-338 https://www.ncbi.nlm.nih.gov/pubmed/27353741
• 110 Ito T, Sugiura T, Okamura Y. et al. The diagnostic advantage of EOB-MR imaging over CT in the detection of liver metastasis in patients with potentially resectable pancreatic cancer. Pancreatology 2017; 17: 451-456 https://pubmed.ncbi.nlm.nih.gov/28298257/
• 111 Jeon SK, Lee JM, Joo I. et al. Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT. European Radiology 2018; 28: 3484-3493 https://pubmed.ncbi.nlm.nih.gov/29352379/
• 112 Kim HJ, Park MS, Lee JY. et al. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma. Cancer Res Treat 2019; 51: 24-33 https://pubmed.ncbi.nlm.nih.gov/29397657/
• 113 Kim HW, Lee JC, Paik KH. et al. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Surgery (United States) 2017; 161: 1579-1587 https://pubmed.ncbi.nlm.nih.gov/28237643/
• 114 Wang L, Dong P, Wang WG. et al. Positron emission tomography modalities prevent futile radical resection of pancreatic cancer: A meta-analysis. International Journal of Surgery 2017; 46: 119-125 https://pubmed.ncbi.nlm.nih.gov/28890410/
• 115 Ghaneh P, Hanson R, Titman A. et al. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Health Technol Assess 2018; 22: 1-114 https://www.ncbi.nlm.nih.gov/pubmed/29402376
• 116 Schachter PP, Avni Y, Shimonov M. et al. The impact of laparoscopy and laparoscopic ultrasonography on the management of pancreatic cancer. Arch Surg 2000; 135: 1303-1307 https://pubmed.ncbi.nlm.nih.gov/11074885/
• 117 Vollmer CM, Drebin JA, Middleton WD. et al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg 2002; 235: 1-7 https://pubmed.ncbi.nlm.nih.gov/11753036/
• 118 Toft J, Hadden WJ, Laurence JM. et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol 2017; 92: 17-23 https://pubmed.ncbi.nlm.nih.gov/28624015/
• 119 European Study Group on Cystic Tumours of the P. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018; 67: 789-804 https://gut.bmj.com/content/67/5/789.long
• 120 van der Waaij LA, van Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc 2005; 62: 383-389 https://pubmed.ncbi.nlm.nih.gov/16111956/
• 121 Tanaka M, Fernández-Del CastilloC, Kamisawa T. et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017; 17: 738-753 https://pubmed.ncbi.nlm.nih.gov/28735806/
• 122 Doi R, Imamura M, Hosotani R. et al. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. Surg Today 2008; 38: 1021-1028 https://pubmed.ncbi.nlm.nih.gov/18958561/
• 123 Ahola R, Siiki A, Vasama K. et al. Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma. Br J Surg 2017; 104: 1532-1538 https://www.ncbi.nlm.nih.gov/pubmed/28517236
• 124 Alsfasser G, Leicht H, Gunster C. et al. Volume-outcome relationship in pancreatic surgery. Br J Surg 2016; 103: 136-143 https://www.ncbi.nlm.nih.gov/pubmed/26505976
• 125 Amini N, Spolverato G, Kim Y. et al. Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery. J Gastrointest Surg 2015; 19: 1581-1592 https://www.ncbi.nlm.nih.gov/pubmed/25794484
• 126 Lidsky ME, Sun Z, Nussbaum DP. et al. Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. Ann Surg 2017; 266: 333-338 https://www.ncbi.nlm.nih.gov/pubmed/27429020
• 127 Stella M, Bissolati M, Gentile D. et al. Impact of surgical experience on management and outcome of pancreatic surgery performed in high- and low-volume centers. Updates Surg 2017; 69: 351-358 https://www.ncbi.nlm.nih.gov/pubmed/28215039
• 128 van der Geest LG, van Rijssen LB, Molenaar IQ. et al. Volume-outcome relationships in pancreatoduodenectomy for cancer. HPB (Oxford) 2016; 18: 317-324 https://www.ncbi.nlm.nih.gov/pubmed/27037200
• 129 Kutlu OC, Lee JE, Katz MH. et al. Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis. Ann Surg 2018; 267: 552-560 https://pubmed.ncbi.nlm.nih.gov/28045744/
• 130 Guller U, Warschkow R, Ackermann CJ. et al. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection. Swiss Med Wkly 2017; 147: w14473 https://www.ncbi.nlm.nih.gov/pubmed/28750418
• 131 Gooiker GA, Lemmens VE, Besselink MG. et al. Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg 2014; 101: 1000-1005 https://www.ncbi.nlm.nih.gov/pubmed/24844590
• 132 Derogar M, Blomberg J, Sadr-Azodi O. Hospital teaching status and volume related to mortality after pancreatic cancer surgery in a national cohort. Br J Surg 2015; 102: 548-557 https://www.ncbi.nlm.nih.gov/pubmed/25711855
• 133 Coupland VH, Konfortion J, Jack RH. et al. Resection rate, hospital procedure volume and survival in pancreatic cancer patients in England: Population-based study, 2005-2009. Eur J Surg Oncol 2016; 42: 190-196 https://www.ncbi.nlm.nih.gov/pubmed/26705143
• 134 Brahmbhatt B, Bhurwal A, Lukens FJ. et al. Pancreatic Surgery in the Older Population: A Single Institution's Experience over Two Decades. Curr Gerontol Geriatr Res 2016; 2016: 8052175 https://www.ncbi.nlm.nih.gov/pubmed/28018428
• 135 Bliss LA, Yang CJ, Chau Z. et al. Patient selection and the volume effect in pancreatic surgery: unequal benefits?. HPB (Oxford) 2014; 16: 899-906 https://www.ncbi.nlm.nih.gov/pubmed/24905343
• 136 Bateni SB, Olson JL, Hoch JS. et al. Drivers of Cost for Pancreatic Surgery: It's Not About Hospital Volume. Ann Surg Oncol 2018; 25: 3804-3811 https://www.ncbi.nlm.nih.gov/pubmed/30218244
• 137 Balzano G, Capretti G, Callea G. et al. Overuse of surgery in patients with pancreatic cancer A nationwide analysis in Italy. HPB (Oxford) 2016; 18: 470-478 https://www.ncbi.nlm.nih.gov/pubmed/27154812
• 138 Schwarz RE. Technical considerations to maintain a low frequency of postoperative biliary stent-associated infections. J Hepatobiliary Pancreat Surg 2002; 9: 93-97 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12021902
• 139 Gerke H, White R, Byrne MF. et al. Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage. Dig Liver Dis 2004; 36: 412-418 https://www.ncbi.nlm.nih.gov/pubmed/15248382
• 140 Jagannath P, Dhir V, Shrikhande S. et al. Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy. Br J Surg 2005; 92: 356-361 https://pubmed.ncbi.nlm.nih.gov/15672425/
• 141 Martignoni ME, Wagner M, Krahenbuhl L. et al. Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy. Am J Surg 2001; 181: 52-59 https://pubmed.ncbi.nlm.nih.gov/11248177/
• 142 Sohn TA, Yeo CJ, Cameron JL. et al. Do preoperative biliary stents increase postpancreaticoduodenectomy complications?. J Gastrointest Surg 2000; 4: 258-267 https://pubmed.ncbi.nlm.nih.gov/10769088/
• 143 van der Gaag NA, Rauws EA, van Eijck CH. et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362: 129-137 http://www.ncbi.nlm.nih.gov/pubmed/20071702
• 144 Allen V, Gurusamy K, Takwoingi Y. et al. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev 2016; 7: CD009323 https://pubmed.ncbi.nlm.nih.gov/27383694/
• 145 De Rosa A, Cameron I, Gomez D. Indications for staging laparoscopy in pancreatic cancer. HPB (Oxford) 2016; 18 (01) 13-20 https://pubmed.ncbi.nlm.nih.gov/26776846/
• 146 Levy J, Tahiri M, Vanounou T. et al. Diagnostic Laparoscopy with Ultrasound Still Has a Role in the Staging of Pancreatic Cancer: A Systematic Review of the Literature. HPB Surg 2016; 2016: 8092109 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829723/
• 147 Ta R, O'Connor D, Sulistijo A. et al. The Role of Staging Laparoscopy in Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Dig Surg 2019; 36 (03) 251-260 https://pubmed.ncbi.nlm.nih.gov/29649825/
• 148 Wagner M, Redaelli C, Lietz M. et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91: 586-594 https://pubmed.ncbi.nlm.nih.gov/15122610/
• 149 Fusai G, Warnaar N, Sabin CA. et al. Outcome of R1 resection in patients undergoing pancreatico-duodenectomy for pancreatic cancer. Eur J Surg Oncol 2008; 34: 1309-1315 https://www.ncbi.nlm.nih.gov/pubmed/18325723
• 150 Gaedcke J, Gunawan B, Grade M. et al. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg 2010; 395: 451-458 https://www.ncbi.nlm.nih.gov/pubmed/19418067
• 151 Hartwig W, Hackert T, Hinz U. et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 2011; 254: 311-319 https://www.ncbi.nlm.nih.gov/pubmed/21606835
• 152 Esposito I, Kleeff J, Bergmann F. et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008; 15: 1651-1660 https://www.ncbi.nlm.nih.gov/pubmed/18351300
• 153 Raut CP, Tseng JF, Sun CC. et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246: 52-60 http://www.ncbi.nlm.nih.gov/pubmed/17592291
• 154 Chang DK, Johns AL, Merrett ND. et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009; 27: 2855-2862 https://www.ncbi.nlm.nih.gov/pubmed/19398572
• 155 Campbell F, Smith RA, Whelan P. et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology 2009; 55: 277-283 https://www.ncbi.nlm.nih.gov/pubmed/19723142
• 156 Jamieson NB, Foulis AK, Oien KA. et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg 2010; 251: 1003-1010 http://www.ncbi.nlm.nih.gov/pubmed/20485150
• 157 Diener MarkusK, Fitzmaurice C, Schwarzer G. et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database of Systematic Reviews 2011; 11: CD006053 https://pubmed.ncbi.nlm.nih.gov/21563148/
• 158 Kawai M, Tani M, Hirono S. et al. Pylorus ring resection reduces delayed gastric emptying in patients undergoing pancreatoduodenectomy: a prospective, randomized, controlled trial of pylorus-resecting versus pylorus-preserving pancreatoduodenectomy. Annals of surgery 2011; 495-501 https://pubmed.ncbi.nlm.nih.gov/21248633/
• 159 Verbeke CS. Resection margins and R1 rates in pancreatic cancer – are we there yet?. Histopathology 2008; 52: 787-96 https://pubmed.ncbi.nlm.nih.gov/18081813/
• 160 Wittekind C, Compton C, Quirke P. et al. A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer 2009; 115: 3483-3488 https://pubmed.ncbi.nlm.nih.gov/19536900/
• 161 van der Geest LG, Besselink MG, Busch OR. et al. Elderly Patients Strongly Benefit from Centralization of Pancreatic Cancer Surgery: A Population-Based Study. Ann Surg Oncol 2016; 23: 2002-2009 https://www.ncbi.nlm.nih.gov/pubmed/26795767
• 162 Gajda M, Kenig J. Treatment outcomes of pancreatic cancer in the elderly – literature review. Folia Med Cracov 2018; 58: 49-66 https://www.ncbi.nlm.nih.gov/pubmed/30521511
• 163 Kim SY, Weinberg L, Christophi C. et al. The outcomes of pancreaticoduodenectomy in patients aged 80 or older: a systematic review and meta-analysis. HPB (Oxford) 2017; 19: 475-482 https://www.ncbi.nlm.nih.gov/pubmed/28292633
• 164 Sukharamwala P, Thoens J, Szuchmacher M. et al. Advanced age is a risk factor for post-operative complications and mortality after a pancreaticoduodenectomy: a meta-analysis and systematic review. HPB (Oxford) 2012; 14: 649-657 https://www.ncbi.nlm.nih.gov/pubmed/22954000
• 165 van der Geest LG, Besselink MG, van Gestel YR. et al. Pancreatic cancer surgery in elderly patients: Balancing between short-term harm and long-term benefit A population-based study in the Netherlands. Acta Oncol 2016; 55: 278-285 https://pubmed.ncbi.nlm.nih.gov/26552841/
• 166 Sho M, Murakami Y, Kawai M. et al. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. J Hepatobiliary Pancreat Sci 2016; 23: 188-197 https://www.ncbi.nlm.nih.gov/pubmed/26763744
• 167 Shirai Y, Shiba H, Horiuchi T. et al. Assessment of Surgical Outcome After Pancreatic Resection in Extremely Elderly Patients. Anticancer Res 2016; 36: 2011-2017 https://www.ncbi.nlm.nih.gov/pubmed/27069195
• 168 Sahakyan MA, Edwin B, Kazaryan AM. et al. Perioperative outcomes and survival in elderly patients undergoing laparoscopic distal pancreatectomy. J Hepatobiliary Pancreat Sci 2017; 24: 42-48 https://www.ncbi.nlm.nih.gov/pubmed/27794204
• 169 Renz BW, Khalil PN, Mikhailov M. et al. Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study. Int J Surg 2016; 28: 118-125 https://pubmed.ncbi.nlm.nih.gov/26906329/
• 170 Miyazaki Y, Kokudo T, Amikura K. et al. Age does not affect complications and overall survival rate after pancreaticoduodenectomy: Single-center experience and systematic review of literature. Biosci Trends 2016; 10: 300-306 https://pubmed.ncbi.nlm.nih.gov/27396698/
• 171 Hsu CC, Wolfgang CL, Laheru DA. et al. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg 2012; 16: 753-761 https://www.ncbi.nlm.nih.gov/pubmed/22311282
• 172 He W, Zhao H, Chan W. et al. Underuse of surgical resection among elderly patients with early-stage pancreatic cancer. Surgery 2015; 158: 1226-1234 https://pubmed.ncbi.nlm.nih.gov/26138347/
• 173 Ansari D, Aronsson L, Fredriksson J. et al. Safety of pancreatic resection in the elderly: a retrospective analysis of 556 patients. Ann Gastroenterol 2016; 29: 221-225 https://www.ncbi.nlm.nih.gov/pubmed/27065736
• 174 Addeo P, Delpero JR, Paye F. et al. Pancreatic fistula after a pancreaticoduodenectomy for ductal adenocarcinoma and its association with morbidity: a multicentre study of the French Surgical Association. HPB (Oxford) 2014; 16: 46-55 https://pubmed.ncbi.nlm.nih.gov/23461663/
• 175 Lyu HG, Sharma G, Brovman E. et al. Risk Factors of Reoperation After Pancreatic Resection. Dig Dis Sci 2017; 62: 1666-1675 https://pubmed.ncbi.nlm.nih.gov/28341868/
• 176 Turrini O, Paye F, Bachellier P. et al. Pancreatectomy for adenocarcinoma in elderly patients: Postoperative outcomes and long term results: A study of the French Surgical Association. European Journal of Surgical Oncology 2013; 39: 171-178 https://pubmed.ncbi.nlm.nih.gov/22999411/
• 177 Tas F, Sen F, Odabas H. et al. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 2013; 18: 839-846 https://www.ncbi.nlm.nih.gov/pubmed/22996141
• 178 Kleeff J, Costello E, Jackson R. et al. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Br J Cancer 2016; 115: 887-894 https://pubmed.ncbi.nlm.nih.gov/27584663/
• 179 Feyko J, Hazard H, Cardinal J. et al. Pancreatectomy in Patients with Impaired Renal Function: How Risky Is It?. Am Surg 2016; 82: 16-21 https://www.ncbi.nlm.nih.gov/pubmed/26802844
• 180 Isaji S, Mizuno S, Windsor JA. et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018; 18: 2-11 https://www.ncbi.nlm.nih.gov/pubmed/29191513
• 181 Khorana AA, Mangu PB, Berlin J. et al. Potenzially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34: 2541-2556 https://pubmed.ncbi.nlm.nih.gov/27247221/
• 182 ZfKD, GEKID. Krebs in Deutschland. Bauchspeicheldrüse. 2016 https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019 / kid_2019_c25_bauchspeicheldruese.pdf?__blob=publicationFile
• 183 Persigehl T, Baumhauer M, Baessler B. et al. Structured Reporting of Solid and Cystic Pancreatic Lesions in CT and MRI: Consensus-Based Structured Report Templates of the German Society of Radiology (DRG). Rofo 2020; 192: 641-656 https://www.ncbi.nlm.nih.gov/pubmed/32615626
• 184 Agalianos C, Gouvas N, Papaparaskeva K. et al. Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features. HPB (Oxford) 2016; 18: 633-641 https://pubmed.ncbi.nlm.nih.gov/27485057/
• 185 Cao F, Li J, Li A. et al. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: A systemic review and metaanalysis. Oncotarget 2017; 8: 15004-15013 https://pubmed.ncbi.nlm.nih.gov/28122342/
• 186 Gebauer F, Damanakis AI, Bruns C. [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy]. Chirurg 2018; 89: 510-515 https://www.ncbi.nlm.nih.gov/pubmed/29557488
• 187 Michalski CW, Erkan M, Huser N. et al. Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg 2008; 25: 473-480 http://www.ncbi.nlm.nih.gov/pubmed/19212120
• 188 Crippa S, Bittoni A, Sebastiani E. et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. European Journal of Surgical Oncology 2016; 42: 1533-1539 https://pubmed.ncbi.nlm.nih.gov/27423449/
• 189 Hempel S, Plodeck V, Mierke F. et al. Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection. Scientific reports 2017; 7: 7688 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=626324641
• 190 Kim Y, Kim SC, Song KB. et al. Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma. HPB 2016; 18: 325-331 https://pubmed.ncbi.nlm.nih.gov/27037201/
• 191 Klaiber U, Schnaidt ES, Hinz U. et al. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Annals of surgery 2021; 273: 154-162 https://pubmed.ncbi.nlm.nih.gov/30921051/
• 192 Lowder CY, Metkus J, Epstein J. et al. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Annals of Surgical Oncology 2018; 25: 4004-4011 https://pubmed.ncbi.nlm.nih.gov/30225835/
• 193 Philips P, Dunki-Jacobs E, Agle SC. et al. The role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery. HPB : the official journal of the International Hepato Pancreato Biliary Association 2014; 16: 1051-1055 https://pubmed.ncbi.nlm.nih.gov/25123504/
• 194 Shi HJ, Jin C, Fu DL. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability. World Journal of Gastroenterology 2016; 22: 10024-10037 https://pubmed.ncbi.nlm.nih.gov/28018110/
• 195 Tachezy M, Gebauer F, Janot M. et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery (United States) 2016; 160: 136-144 https://pubmed.ncbi.nlm.nih.gov/27048934/
• 196 Gleisner AL, Assumpcao L, Cameron JL. et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?. Cancer 2007; 110: 2484-2492 https://pubmed.ncbi.nlm.nih.gov/17941009/
• 197 Shrikhande SV, Kleeff J, Reiser C. et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 2007; 14: 118-127 http://www.ncbi.nlm.nih.gov/pubmed/17066229
• 198 Takada T, Yasuda H, Amano H. et al. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival?. Hepatogastroenterology 1997; 44: 567-573 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9164539
• 199 Massucco P, Ribero D, Sgotto E. et al. Prognostic significance of lymph node metastases in pancreatic head cancer treated with extended lymphadenectomy: not just a matter of numbers. Ann Surg Oncol 2009; 16: 3323-3332 http://www.ncbi.nlm.nih.gov/pubmed/19777195
• 200 Doi R, Kami K, Ito D. et al. Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer. World J Surg 2007; 31: 147-154 https://www.ncbi.nlm.nih.gov/pubmed/17171496
• 201 Kanda M, Fujii T, Nagai S. et al. Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas 2011; 40: 951-955 http://dx.doi.org/10.1097/MPA.0b013e3182148342
• 202 Cordera F, Arciero CA, Li T. et al. Significance of common hepatic artery lymph node metastases during pancreaticoduodenectomy for pancreatic head adenocarcinoma. Ann Surg Oncol 2007; 14: 2330-2336 https://www.ncbi.nlm.nih.gov/pubmed/17492334
• 203 Yamada S, Nakao A, Fujii T. et al. Pancreatic cancer with paraaortic lymph node metastasis: a contraindication for radical surgery?. Pancreas 2009; 38: e13-e17 https://pubmed.ncbi.nlm.nih.gov/18797422/
• 204 Tao L, Yuan C, Ma Z. et al. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: A population-based study. Cancer Management and Research 2017; 9: 471-479 https://pubmed.ncbi.nlm.nih.gov/29056856/
• 205 Liu X, Fu Y, Chen Q. et al. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. BMC Gastroenterology 2018; 18: 168 https://pubmed.ncbi.nlm.nih.gov/30400836/
• 206 Schwarz M, Isenmann R, Thomsen J. et al. Efficacy of oral ofloxacin for single-dose perioperative prophylaxis in general surgery--a controlled randomized clinical study. Langenbecks Arch Surg 2001; 386: 397-401 http://www.ncbi.nlm.nih.gov/pubmed/11735011
• 207 Targarona EM, Garau J, Munoz-Ramos C. et al. Single-dose antibiotic prophylaxis in patients at high risk for infection in biliary surgery: a prospective and randomized study comparing cefonicid with mezlocillin. Surgery 1990; 107: 327-334 https://pubmed.ncbi.nlm.nih.gov/2106732/
• 208 Kujath P, Bouchard R, Scheele J. et al. [Current perioperative antibiotic prophylaxis]. Chirurg 2006; 77: 490-492 https://pubmed.ncbi.nlm.nih.gov/16773347/
• 209 Barnett SP, Hodul PJ, Creech S. et al. Octreotide does not prevent postoperative pancreatic fistula or mortality following Pancreaticoduodenectomy. Am Surg 2004; 70: 222-226 https://www.ncbi.nlm.nih.gov/pubmed/15055845
• 210 Friess H, Buchler MW. Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders. Digestion 1996; 57 (Suppl. 01) 97-102 https://www.ncbi.nlm.nih.gov/pubmed/8813484
• 211 Gouillat C, Chipponi J, Baulieux J. et al. Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy. Br J Surg 2001; 88: 1456-1462 https://www.ncbi.nlm.nih.gov/pubmed/11683740
• 212 Hesse UJ, DeDecker C, Houtmeyers P. et al. Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy. World J Surg 2005; 29: 1325-1328 http://www.ncbi.nlm.nih.gov/pubmed/16132406
• 213 Montorsi M, Zago M, Mosca F. et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 1995; 117: 26-31 http://www.ncbi.nlm.nih.gov/pubmed/7809832
• 214 Pederzoli P, Bassi C, Falconi M. et al. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery Italian Study Group. Br J Surg 1994; 81: 265-269 http://www.ncbi.nlm.nih.gov/pubmed/8156354
• 215 Yeo CJ, Cameron JL, Lillemoe KD. et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000; 232: 419-429 https://pubmed.ncbi.nlm.nih.gov/10973392/
• 216 Connor S, Alexakis N, Garden OJ. et al. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 2005; 92: 1059-1067 https://www.ncbi.nlm.nih.gov/pubmed/16044410
• 217 Konishi M, Kinoshita T, Nakagohri T. et al. Prognostic value of cytologic examination of peritoneal washings in pancreatic cancer. Arch Surg 2002; 137: 475-480 https://pubmed.ncbi.nlm.nih.gov/11926958/
• 218 Yachida S, Fukushima N, Sakamoto M. et al. Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg 2002; 89: 573-578 https://pubmed.ncbi.nlm.nih.gov/11972546/
• 219 Heeckt P, Safi F, Binder T. et al. [Free intraperitoneal tumors cells in pancreatic cancer--significance for clinical course and therapy]. Chirurg 1992; 63: 563-567 https://pubmed.ncbi.nlm.nih.gov/1380421/
• 220 Kinoshita T, Ozaki H, Kosuge T. et al. [Effectiveness of intraoperative cytological examination of peritoneal washings for patients with pancreatic cancer]. Nihon Geka Gakkai Zasshi 1992; 93: 1410-1415 https://pubmed.ncbi.nlm.nih.gov/1448048/
• 221 Makary MA, Warshaw AL, Centeno BA. et al. Implications of peritoneal cytology for pancreatic cancer management. Arch Surg 1998; 133: 361-365 https://pubmed.ncbi.nlm.nih.gov/9565114/
• 222 Nakao A, Oshima K, Takeda S. et al. Peritoneal washings cytology combined with immunocytochemical staining in pancreatic cancer. Hepatogastroenterology 1999; 46: 2974-2977 https://pubmed.ncbi.nlm.nih.gov/10576385/
• 223 Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991; 161: 26-29 https://pubmed.ncbi.nlm.nih.gov/1824810/
• 224 Bachellier P, Nakano H, Oussoultzoglou PD. et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?. Am J Surg 2001; 182: 120-129 https://www.ncbi.nlm.nih.gov/pubmed/11574081
• 225 Bassi C, Stocken DD, Olah A. et al. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Dig Surg 2005; 22: 353-363 https://www.ncbi.nlm.nih.gov/pubmed/16293966
• 226 Capussotti L, Massucco P, Ribero D. et al. Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 2003; 138: 1316-1322 https://www.ncbi.nlm.nih.gov/pubmed/14662531
• 227 Farnell MB, Pearson RK, Sarr MG. et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138: 618-628 https://www.ncbi.nlm.nih.gov/pubmed/16269290
• 228 Fernandez-del CastilloC, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg 1995; 130: 295-299 https://www.ncbi.nlm.nih.gov/pubmed/7887797
• 229 Hartel M, Niedergethmann M, Farag-Soliman M. et al. Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg 2002; 168: 707-712 https://www.ncbi.nlm.nih.gov/pubmed/15362580
• 230 Ishikawa O, Ohigashi H, Sasaki Y. et al. Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery 1997; 121: 244-249 http://www.ncbi.nlm.nih.gov/pubmed/9068665
• 231 Jurowich C, Meyer W, Adamus R. et al. [Portal vein resection in the framework of surgical therapy of pancreatic head carcinoma: clarification of indication by improved preoperative diagnostic procedures?]. Chirurg 2000; 71: 803-807 http://www.ncbi.nlm.nih.gov/pubmed/10986602
• 232 Kawarada Y, Yokoi H, Isaji S. et al. Modified standard pancreaticoduodenectomy for the treatment of pancreatic head cancer. Digestion 1999; 60 (Suppl. 01) 120-125 http://www.ncbi.nlm.nih.gov/pubmed/10026445
• 233 Klempnauer J, Ridder GJ, Bektas H. et al. Extended resections of ductal pancreatic cancer--impact on operative risk and prognosis. Oncology 1996; 53: 47-53 http://www.ncbi.nlm.nih.gov/pubmed/8570131
• 234 Klinkenbijl JH, van der Schelling GP, Hop WC. et al. The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg 1992; 216: 142-145 http://www.ncbi.nlm.nih.gov/pubmed/1354435
• 235 Kremer B, Vogel I, Luttges J. et al. Surgical possibilities for pancreatic cancer: extended resection. Ann Oncol 1999; 10 (Suppl. 04) 252-256 http://www.ncbi.nlm.nih.gov/pubmed/10436834
• 236 Lin PW, Shan YS, Lin YJ. et al. Pancreaticoduodenectomy for pancreatic head cancer: PPPD versus Whipple procedure. Hepatogastroenterology 2005; 52: 1601-1604 http://www.ncbi.nlm.nih.gov/pubmed/16201125
• 237 Lygidakis NJ, Singh G, Bardaxoglou E. et al. Mono-bloc total spleno-pancreaticoduodenectomy for pancreatic head carcinoma with portal-mesenteric venous invasion A prospective randomized study. Hepatogastroenterology 2004; 51: 427-433 http://www.ncbi.nlm.nih.gov/pubmed/15086174
• 238 Mu DQ, Peng SY, Wang GF. Extended radical operation of pancreatic head cancer: appraisal of its clinical significance. World J Gastroenterol 2005; 11: 2467-2471 http://www.ncbi.nlm.nih.gov/pubmed/15832419
• 239 Nakao A, Takeda S, Sakai M. et al. Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection. Pancreas 2004; 28: 289-292 http://www.ncbi.nlm.nih.gov/pubmed/15084973
• 240 Pedrazzoli S, DiCarlo V, Dionigi R. et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study Lymphadenectomy Study Group. Ann Surg 1998; 228: 508-517 https://pubmed.ncbi.nlm.nih.gov/9790340/
• 241 Roher HD, Heise JW, Goretzki PE. [Stomach saving duodenopancreatectomy Indications and contraindications The most important surgical steps]. Zentralbl Chir 2000; 125: 961-965 http://www.ncbi.nlm.nih.gov/pubmed/11190613
• 242 Schafer M, Mullhaupt B, Clavien PA. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg 2002; 236: 137-148 http://www.ncbi.nlm.nih.gov/pubmed/12170018
• 243 Takada T, Yasuda H, Amano H. et al. Results of a pylorus-preserving pancreatoduodenectomy for pancreatic cancer: a comparison with results of the Whipple procedure. Hepatogastroenterology 1997; 44: 1536-1540 http://www.ncbi.nlm.nih.gov/pubmed/9427018
• 244 Tran KT, Smeenk HG, van Eijck CH. et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg 2004; 240: 738-745 http://www.ncbi.nlm.nih.gov/pubmed/15492552
• 245 Tseng JF, Raut CP, Lee JE. et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004; 8: 935-949 http://www.ncbi.nlm.nih.gov/pubmed/15585381
• 246 Zerbi A, Balzano G, Patuzzo R. et al. Comparison between pylorus-preserving and Whipple pancreatoduodenectomy. Br J Surg 1995; 82: 975-979 https://pubmed.ncbi.nlm.nih.gov/7648124/
• 247 Diener MK, Knaebel HP, Heukaufer C. et al. A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg 2007; 245: 187-200 https://pubmed.ncbi.nlm.nih.gov/17245171/
• 248 Christein JD, Kendrick ML, Iqbal CW. et al. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005; 9: 922-927 https://www.ncbi.nlm.nih.gov/pubmed/16137585
• 249 Gebhardt C, Meyer W, Jurowich C. [Is resection of left-sided ductal pancreatic carcinoma of value?]. Zentralbl Chir 2000; 125: 966-969 https://www.ncbi.nlm.nih.gov/pubmed/11190614
• 250 Kayahara M, Nagakawa T, Ueno K. et al. Distal pancreatectomy--does it have a role for pancreatic body and tail cancer. Hepatogastroenterology 1998; 45: 827-832 http://www.ncbi.nlm.nih.gov/pubmed/9684142
• 251 Mayumi T, Nimura Y, Kamiya J. et al. Distal pancreatectomy with en bloc resection of the celiac artery for carcinoma of the body and tail of the pancreas. Int J Pancreatol 1997; 22: 15-21 http://www.ncbi.nlm.nih.gov/pubmed/9387020
• 252 Shimada K, Sakamoto Y, Sano T. et al. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery 2006; 139: 288-295 https://pubmed.ncbi.nlm.nih.gov/16546491/
• 253 Shoup M, Conlon KC, Klimstra D. et al. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?. J Gastrointest Surg 2003; 7: 946-952 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14675703
• 254 Kondo S, Katoh H, Hirano S. et al. Results of radical distal pancreatectomy with en bloc resection of the celiac artery for locally advanced cancer of the pancreatic body. Langenbecks Arch Surg 2003; 388: 101-106 http://www.ncbi.nlm.nih.gov/pubmed/12684805
• 255 Choi S, Han H, Park P. et al. Systematic review of the clinical significance of lymph node micrometastases of pancreatic adenocarcinoma following surgical resection. Pancreatology 2017; 17 (03) 342-349 https://pubmed.ncbi.nlm.nih.gov/28336226/
• 256 Dasari B, Pasquali S, Vohra R. et al. Extended Versus Standard Lymphadenectomy for Pancreatic Head Cancer: Meta-Analysis of Randomized Controlled Trials. J Gastrointest Surg 2015; 19 (09) 1725-1732 https://pubmed.ncbi.nlm.nih.gov/26055135/
• 257 Elshaer M, Gravante G, Kosmin M. et al. A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. Ann R Coll Surg Engl 2017; 99 (02) 101-106 https://pubmed.ncbi.nlm.nih.gov/27869496/
• 258 Karjol U, Chandranath A, Jonnada P. et al. Lymph Node Ratio as a Prognostic Marker in Pancreatic Cancer Survival: A Systematic Review and Meta-Analysis. Cureus 2020; 12 (08) e9597 https://pubmed.ncbi.nlm.nih.gov/32789099/
• 259 Ke K, Chen W, Chen Y. Standard and extended lymphadenectomy for adenocarcinoma of the pancreatic head: a meta-analysis and systematic review. J Gastroenterol Hepatol 2014; 29 (03) 453-462 https://pubmed.ncbi.nlm.nih.gov/24164704/
• 260 Kotb A, Hajibandeh S, Hajibandeh S. et al. Meta-analysis and trial sequential analysis of randomised controlled trials comparing standard versus extended lymphadenectomy in pancreatoduodenectomy for adenocarcinoma of the head of pancreas. Langenbecks Arch Surg 2021; 406 (03) 547-561 https://pubmed.ncbi.nlm.nih.gov/32978673/
• 261 Orci L, Meyer J, Combescure C. et al. A meta-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. HPB (Oxford) 2015; 17 (07) 565-572 https://pubmed.ncbi.nlm.nih.gov/25913578/
• 262 Pedrazzoli S. Extent of lymphadenectomy to associate with pancreaticoduodenectomy in patients with pancreatic head cancer for better tumor staging. Cancer Treat Rev 2015; 41 (07) 577-587 https://pubmed.ncbi.nlm.nih.gov/26045226/
• 263 Staerkle R, Vuille-Dit-Bille R, Soll C. et al. Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma. Cochrane Database Syst Rev 2021; 1: CD011490 https://pubmed.ncbi.nlm.nih.gov/33471373/
• 264 Svoronos C, Tsoulfas G, Katsourakis A. et al. Role of extended lymphadenectomy in the treatment of pancreatic head adenocarcinoma: review and meta-analysis. ANZ J Surg 2014; 84 (10) 706-711 https://pubmed.ncbi.nlm.nih.gov/24165093/
• 265 Wang W, He Y, Wu L. et al. Efficacy of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic head adenocarcinoma An update meta-analysis. Pancreatology 2019; 19 (08) 1074-1080 https://pubmed.ncbi.nlm.nih.gov/31668841/
• 266 Franceschilli M, Vinci D, Di Carlo S. et al. Central vascular ligation and mesentery based abdominal surgery. Discov Oncol 2021; 12 (01) 24 https://pubmed.ncbi.nlm.nih.gov/35201479/
• 267 Bhatti I, Peacock O, Awan AK. et al. Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma. World J Surg 2010; 34: 768-775 https://pubmed.ncbi.nlm.nih.gov/20052471/
• 268 Garcea G, Dennison AR, Ong SL. et al. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007; 33: 892-897 https://pubmed.ncbi.nlm.nih.gov/17398060/
• 269 Hellan M, Sun CL, Artinyan A. et al. The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas 2008; 37: 19-24 https://pubmed.ncbi.nlm.nih.gov/18580439/
• 270 House MG, Gonen M, Jarnagin WR. et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 2007; 11: 1549-1555 https://pubmed.ncbi.nlm.nih.gov/17786531/
• 271 Konstantinidis IT, Deshpande V, Zheng H. et al. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?. J Gastrointest Surg 2010; 14: 261-267 https://pubmed.ncbi.nlm.nih.gov/19937477/
• 272 La Torre M, Cavallini M, Ramacciato G. et al. Role of the Lymph node ratio in pancreatic ductal adenocarcinoma Impact on patient stratification and prognosis. Journal of Surgical Oncology 2011; 104: 629-633 https://pubmed.ncbi.nlm.nih.gov/21713779/
• 273 Murakami Y, Uemura K, Sudo T. et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 2010; 211: 196-204 https://pubmed.ncbi.nlm.nih.gov/20670857/
• 274 Pai RK, Beck AH, Mitchem J. et al. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease. Am J Surg Pathol 2011; 35: 228-234 https://pubmed.ncbi.nlm.nih.gov/21263243/
• 275 Pawlik TM, Gleisner AL, Cameron JL. et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007; 141: 610-618 https://pubmed.ncbi.nlm.nih.gov/17462460/
• 276 Prenzel KL, Holscher AH, Vallbohmer D. et al. Lymph node size and metastatic infiltration in adenocarcinoma of the pancreatic head. Eur J Surg Oncol 2010; 36: 993-996 https://pubmed.ncbi.nlm.nih.gov/20594789/
• 277 Riediger H, Keck T, Wellner U. et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009; 13: 1337-1344 https://pubmed.ncbi.nlm.nih.gov/19418101/
• 278 Sahin TT, Fujii T, Kanda M. et al. Prognostic Implications of Lymph Node Metastases in Carcinoma of the Body and Tail of the Pancreas. Pancreas 2011; 40: 1029-1033 https://pubmed.ncbi.nlm.nih.gov/21705947/
• 279 Showalter TN, Winter KA, Berger AC. et al. The Influence of Total Nodes Examined, Number of Positive Nodes, and Lymph Node Ratio on Survival after Surgical Resection and Adjuvant Chemoradiation for Pancreatic Cancer: A Secondary Analysis of RTOG 9704. Int J Radiat Oncol Biol Phys 2011; 81: 1328-1335 https://pubmed.ncbi.nlm.nih.gov/20934270/
• 280 Slidell MB, Chang DC, Cameron JL. et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008; 15: 165-174 https://pubmed.ncbi.nlm.nih.gov/17896141/
• 281 Murakami Y, Uemura K, Sudo T. et al. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma. World J Surg 2010; 34: 1900-1907 http://www.ncbi.nlm.nih.gov/pubmed/20376442
• 282 Chen S, Zhan Q, Jin JB. et al. Robot-assisted laparoscopic versus open middle pancreatectomy: short-term results of a randomized controlled trial. Surg Endosc 2017; 31: 962-971 https://www.ncbi.nlm.nih.gov/pubmed/27402095
• 283 Xourafas D, Ashley SW, Clancy TE. Comparison of Perioperative Outcomes between Open, Laparoscopic, and Robotic Distal Pancreatectomy: an Analysis of 1815 Patients from the ACS-NSQIP Procedure-Targeted Pancreatectomy Database. J Gastrointest Surg 2017; 21: 1442-1452 https://pubmed.ncbi.nlm.nih.gov/28573358/
• 284 Mirkin KA, Greenleaf EK, Hollenbeak CS. et al. Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resected pancreatic cancer. Surg Endosc 2018; 32: 2387-2396 https://pubmed.ncbi.nlm.nih.gov/29101568/
• 285 Kauffmann EF, Napoli N, Menonna F. et al. A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status. Surgical Endoscopy 2019; 33: 234-242 https://pubmed.ncbi.nlm.nih.gov/29943061/
• 286 Boggi U, Napoli N, Costa F. et al. Robotic-Assisted Pancreatic Resections. World J Surg 2016; 40: 2497-2506 https://www.ncbi.nlm.nih.gov/pubmed/27206401
• 287 Adam MA, Thomas S, Youngwirth L. et al. Defining a Hospital Volume Threshold for Minimally Invasive Pancreaticoduodenectomy in the United States. JAMA Surg 2017; 152: 336-342 https://www.ncbi.nlm.nih.gov/pubmed/28030713
• 288 Abu HilalM, Hamdan M, Di Fabio F. et al. Laparoscopic versus open distal pancreatectomy: a clinical and cost-effectiveness study. Surg Endosc 2012; 26: 1670-1674 https://pubmed.ncbi.nlm.nih.gov/22179475/
• 289 Raoof M, Ituarte PHG, Woo Y. et al. Propensity score-matched comparison of oncological outcomes between laparoscopic and open distal pancreatic resection. The British journal of surgery 2018; 105: 578-586 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=625133363
• 290 Shimada K, Nara S, Esaki M. et al. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas. Pancreas 2011; 40: 464-468 https://pubmed.ncbi.nlm.nih.gov/21289526/
• 291 Zacharias T, Jaeck D, Oussoultzoglou E. et al. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2007; 11: 350-356 https://pubmed.ncbi.nlm.nih.gov/17458610/
• 292 Wasif N, Ko CY, Farrell J. et al. Impact of tumor grade on prognosis in pancreatic cancer: Should we include grade in AJCC staging?. Annals of Surgical Oncology 2010; 17: 2312-2320 https://pubmed.ncbi.nlm.nih.gov/20422460/
• 293 Fujita T, Nakagohri T, Gotohda N. et al. Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas. Pancreas 2010; 39: e48-e54 https://pubmed.ncbi.nlm.nih.gov/19910836/
• 294 Lee SE, Jang JY, Kim MA. et al. Clinical implications of immunohistochemically demonstrated lymph node micrometastasis in resectable pancreatic cancer. J Korean Med Sci 2011; 26: 881-885 http://www.ncbi.nlm.nih.gov/pubmed/21738340
• 295 Kanda M, Fujii T, Sahin TT. et al. Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas. Ann Surg 2010; 251: 483-487 http://www.ncbi.nlm.nih.gov/pubmed/20101172
• 296 Boggi U, Del Chiaro M, Croce C. et al. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery 2009; 146: 869-881 https://pubmed.ncbi.nlm.nih.gov/19744432/
• 297 Fatima J, Schnelldorfer T, Barton J. et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg 2010; 145: 167-172 https://pubmed.ncbi.nlm.nih.gov/20157085/
• 298 Kurahara H, Takao S, Maemura K. et al. Impact of lymph node micrometastasis in patients with pancreatic head cancer. World J Surg 2007; 31: 483-490 https://pubmed.ncbi.nlm.nih.gov/17219277/
• 299 Menon KV, Gomez D, Smith AM. et al. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) 2009; 11: 18-24 https://pubmed.ncbi.nlm.nih.gov/19590619/
• 300 Mitsunaga S, Hasebe T, Kinoshita T. et al. Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact. Am J Surg Pathol 2007; 31: 1636-1644 https://pubmed.ncbi.nlm.nih.gov/18059219/
• 301 Bernard V, Kim DU, San Lucas FA. et al. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology 2019; 156: 108-118.e4 https://www.ncbi.nlm.nih.gov/pubmed/30240661
• 302 Tsai S, George B, Wittmann D. et al. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Ann Surg 2020; 271: 740-747 https://pubmed.ncbi.nlm.nih.gov/30312198/
• 303 Akita H, Takahashi H, Ohigashi H. et al. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Eur J Surg Oncol 2017; 43: 1061-1067 https://pubmed.ncbi.nlm.nih.gov/28389044/
• 304 Aldakkak M, Christians KK, Krepline AN. et al. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB : the official journal of the International Hepato Pancreato Biliary Association 2015; 17: 942-952 https://pubmed.ncbi.nlm.nih.gov/26255895/
• 305 Aoki S, Motoi F, Murakami Y. et al. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer 2019; 19: 252 https://www.ncbi.nlm.nih.gov/pubmed/30898101
• 306 Oettle H, Post S, Neuhaus P. et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277 http://www.ncbi.nlm.nih.gov/pubmed/17227978
• 307 Ueno H, Kosuge T, Matsuyama Y. et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101: 908-915 http://www.ncbi.nlm.nih.gov/pubmed/19690548
• 308 Neoptolemos JP, Stocken DD, Friess H. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15028824
• 309 Stocken DD, Buchler MW, Dervenis C. et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92: 1372-1381 https://pubmed.ncbi.nlm.nih.gov/15812554/
• 310 Neoptolemos JP, Stocken DD, Bassi C. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081 http://www.ncbi.nlm.nih.gov/pubmed/20823433
• 311 Yoshitomi H, Togawa A, Kimura F. et al. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 2008; 113: 2448-2456 https://pubmed.ncbi.nlm.nih.gov/18823024/
• 312 Neoptolemos JP, Palmer DH, Ghaneh P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet 2017; 389 https://pubmed.ncbi.nlm.nih.gov/28129987/
• 313 Conroy T, Hammel P, Hebbar M. et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New England Journal of Medicine 2018; 379: 2395-5406 https://pubmed.ncbi.nlm.nih.gov/30575490/
• 314 Oettle H, Neuhaus P, Hochhaus A. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA: Journal of the American Medical Association 2013; 310: 1473-1481 https://pubmed.ncbi.nlm.nih.gov/24104372/
• 315 Sinn M, Bahra M, Liersch T. et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. Journal of Clinical Oncology 2017; 35: 3330-3337 https://pubmed.ncbi.nlm.nih.gov/28817370/
• 316 Valle JW, Palmer D, Jackson R. et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study. Journal of Clinical Oncology 2014; 32: 504-512 https://pubmed.ncbi.nlm.nih.gov/24419109/
• 317 Saeed H, Hnoosh D, Huang B. et al. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. Journal of Surgical Oncology 2016; 114: 451-455 https://pubmed.ncbi.nlm.nih.gov/27238300/
• 318 Sun W, Leong CN, Zhang Z. et al. Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat Oncol 2010; 5: 28 https://pubmed.ncbi.nlm.nih.gov/20398316/
• 319 Kalser MH, Ellenberg SS. Pancreatic cancer Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=4015380
• 320 Smeenk HG, van Eijck CH, Hop WC. et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007; 246: 734-740 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17968163
• 321 Morak MJ, van der Gaast A, Incrocci L. et al. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg 2008; 248: 1031-1041 https://pubmed.ncbi.nlm.nih.gov/19092348/
• 322 Neoptolemos JP, Dunn JA, Stocken DD. et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-1585 https://pubmed.ncbi.nlm.nih.gov/11716884/
• 323 Carter R, Stocken DD, Ghaneh P. et al. Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data. Int J Cancer 2009; 124: 2960-2965 https://www.ncbi.nlm.nih.gov/pubmed/19330830
• 324 Klinkenbijl JH, Jeekel J, Sahmoud T. et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-782 https://pubmed.ncbi.nlm.nih.gov/10615932/
• 325 Van Laethem JL, Hammel P, Mornex F. et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010; 28: 4450-4456 https://pubmed.ncbi.nlm.nih.gov/20837948/
• 326 Regine WF, Winter KA, Abrams R. et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the US Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011; 18: 1319-1326 https://pubmed.ncbi.nlm.nih.gov/21499862/
• 327 Reni M, Balzano G, Aprile G. et al. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: A randomized phase II trial. Annals of Surgical Oncology 2012; 19: 2256-2263 https://pubmed.ncbi.nlm.nih.gov/22237835/
• 328 Bosset JF, Pavy JJ, Gillet M. et al. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer: results of a prospective study. Radiother Oncol 1992; 24: 191-194 https://www.ncbi.nlm.nih.gov/pubmed/1357725
• 329 Brunner TB, Merkel S, Grabenbauer GG. et al. Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. Int J Radiat Oncol Biol Phys 2005; 62: 1021-1029 https://www.ncbi.nlm.nih.gov/pubmed/15990004
• 330 Yeo CJ, Abrams RA, Grochow LB. et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival A prospective, single-institution experience. Ann Surg 1997; 225: 621-633 https://pubmed.ncbi.nlm.nih.gov/9193189/
• 331 Herman JM, Swartz MJ, Hsu CC. et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008; 26: 3503-3510 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18640931
• 332 Butturini G, Stocken DD, Wente MN. et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008; 143: 75-83 https://www.ncbi.nlm.nih.gov/pubmed/18209156
• 333 Hishinuma S, Ogata Y, Tomikawa M. et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006; 10: 511-518 http://www.ncbi.nlm.nih.gov/pubmed/16627216
• 334 Andriulli A, Festa V, Botteri E. et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012; 19: 1644-1662 https://www.ncbi.nlm.nih.gov/pubmed/22012027
• 335 Assifi MM, Lu X, Eibl G. et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011; 150: 466-473 https://www.ncbi.nlm.nih.gov/pubmed/21878232
• 336 Bradley A, Van Der Meer R. Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis. Sci Rep 2019; 9: 4354 https://www.ncbi.nlm.nih.gov/pubmed/30867522
• 337 Gillen S, Schuster T, Meyer Zum Buschenfelde C. et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267 https://www.ncbi.nlm.nih.gov/pubmed/20422030
• 338 Palmer DH, Stocken DD, Hewitt H. et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007; 14: 2088-2096 http://www.ncbi.nlm.nih.gov/pubmed/17453298
• 339 Versteijne E, Suker M, Groothuis K. et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 2020; 38: JCO1902274 https://www.ncbi.nlm.nih.gov/pubmed/32105518
• 340 Barbier L, Turrini O, Gregoire E. et al. Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival. HPB (Oxford) 2011; 13: 64-69 https://www.ncbi.nlm.nih.gov/pubmed/21159106
• 341 Takahashi S, Kinoshita T, Konishi M. et al. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci 2011; 18: 567-574 http://www.ncbi.nlm.nih.gov/pubmed/21331805
• 342 Chun YS, Cooper HS, Cohen SJ. et al. Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol 2011; 18: 3601-3607 https://www.ncbi.nlm.nih.gov/pubmed/21947697
• 343 Heinrich S, Schafer M, Weber A. et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 2008; 248: 1014-1022 http://www.ncbi.nlm.nih.gov/pubmed/19092346
• 344 Lutfi W, Talamonti MS, Kantor O. et al. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery (United Kingdom) 2016; 160: 714-724 https://pubmed.ncbi.nlm.nih.gov/27422328/
• 345 Czosnyka NM, Borgert AJ, Smith TJ. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes – an American College of Surgeons National Surgical Quality Improvement Program targeted variable review. HPB (Oxford) 2017; 19: 927-932 https://www.ncbi.nlm.nih.gov/pubmed/28747265
• 346 de Geus SW, Eskander MF, Bliss LA. et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Surgery 2017; 161: 592-601 https://www.ncbi.nlm.nih.gov/pubmed/28341441
• 347 Mirkin KA, Hollenbeak CS, Wong J. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. International Journal of Surgery 2016; 34: 96-102 https://pubmed.ncbi.nlm.nih.gov/27573691/
• 348 Versteijne E, Vogel JA, Besselink MG. et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. The British journal of surgery 2018; 105: 946-958 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033157/pdf/BJS-105-946.pdf
• 349 Mokdad AA, Minter RM, Hong Z. et al. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Journal of Clinical Oncology 2017; 35: 515-522 https://pubmed.ncbi.nlm.nih.gov/27621388/
• 350 Truty MJ, Kendrick ML, Nagorney DM. et al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Annals of surgery 2019; https://pubmed.ncbi.nlm.nih.gov/30946090/
• 351 de Geus SW, Evans DB, Bliss LA. et al. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. Eur J Surg Oncol 2016; 42: 1552-1560 https://www.ncbi.nlm.nih.gov/pubmed/27570116
• 352 Franko J, Hsu HW, Thirunavukarasu P. et al. Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: Impact on perioperative mortality and long-term survival. Eur J Surg Oncol 2017; 43: 351-357 https://www.ncbi.nlm.nih.gov/pubmed/27863846
• 353 Fisher AV, Abbott DE, Venkatesh M. et al. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer. Ann Surg Oncol 2018; 25: 2661-2668 https://www.ncbi.nlm.nih.gov/pubmed/30003452
• 354 Hartwig W, Strobel O, Hinz U. et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 2013; 20: 2188-2196 https://www.ncbi.nlm.nih.gov/pubmed/23247983
• 355 Hammel P, Huguet F, Van Laethem JL. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA: Journal of the American Medical Association 2016; 315: 1844-1853 https://pubmed.ncbi.nlm.nih.gov/27139057/
• 356 Jang JY, Han Y, Lee H. et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Annals of surgery 2018; 268: 215-222 https://pubmed.ncbi.nlm.nih.gov/29462005/
• 357 Chen X, Liu G, Wang K. et al. Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis. Oncotarget 2017; 8: 47831-47840 https://www.ncbi.nlm.nih.gov/pubmed/28599299
• 358 Gemenetzis G, Groot VP, Blair AB. et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Annals of surgery 2019; https://pubmed.ncbi.nlm.nih.gov/29596120/
• 359 Hackert T, Sachsenmaier M, Hinz U. et al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Ann Surg 2016; 264: 457-463 https://www.ncbi.nlm.nih.gov/pubmed/27355262
• 360 Nagakawa Y, Sahara Y, Hosokawa Y. et al. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery. Annals of Surgical Oncology 2019; 26: 1629-1636 https://pubmed.ncbi.nlm.nih.gov/30610555/
• 361 Pietrasz D, Turrini O, Vendrely V. et al. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. Annals of Surgical Oncology 2019; 26: 109-117 https://pubmed.ncbi.nlm.nih.gov/30362063/
• 362 Kasperk R, Klever P, Andreopoulos D. et al. Intraoperative radiotherapy for pancreatic carcinoma. Br J Surg 1995; 82: 1259-1261 http://www.ncbi.nlm.nih.gov/pubmed/7552013
• 363 Reni M, Panucci MG, Ferreri AJ. et al. Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2001; 50: 651-658 http://www.ncbi.nlm.nih.gov/pubmed/11395232
• 364 Yamaguchi K, Nakamura K, Kobayashi K. et al. ERT following IORT improves survival of patients with resectable pancreatic cancer. Hepatogastroenterology 2005; 52: 1244-1249 https://pubmed.ncbi.nlm.nih.gov/16001672/
• 365 Messick C, Hardacre JM, McGee MF. et al. Early experience with intraoperative radiotherapy in patients with resected pancreatic adenocarcinoma. Am J Surg 2008; 195: 308-311 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18207129
• 366 Showalter TN, Rao AS, Rani AnneP. et al. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis. Ann Surg Oncol 2009; 16: 2116-2122 http://www.ncbi.nlm.nih.gov/pubmed/19437078
• 367 Ruano-Ravina A, Almazan OrtegaR, Guedea F. Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother Oncol 2008; 87: 318-325 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18199514
• 368 Zygogianni GA, Kyrgias G, Kouvaris J. et al. Intraoperative radiation therapy on pancreatic cancer patients: a review of the literature. Minerva Chir 2011; 66: 361-369 https://pubmed.ncbi.nlm.nih.gov/21873971/
• 369 Karasawa K, Sunamura M, Okamoto A. et al. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study. Radiother Oncol 2008; 87: 326-330 https://pubmed.ncbi.nlm.nih.gov/18342968/
• 370 Suker M, Beumer BR, Sadot E. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology 2016; 17: 801-810 https://pubmed.ncbi.nlm.nih.gov/27160474/
• 371 Mallinson CN, Rake MO, Cocking JB. et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980; 281: 1589-1591 https://pubmed.ncbi.nlm.nih.gov/7004559/
• 372 Palmer KR, Kerr M, Knowles G. et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-885 https://pubmed.ncbi.nlm.nih.gov/8044610/
• 373 Glimelius B, Hoffman K, Sjoden PO. et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600 https://pubmed.ncbi.nlm.nih.gov/8879373/
• 374 Yip D, Karapetis C, Strickland A. et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006; 3: CD002093 https://pubmed.ncbi.nlm.nih.gov/16855985/
• 375 Wainberg Z, Melisi D, Macarulla T. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023; 402: 1272-1281 https://pubmed.ncbi.nlm.nih.gov/37708904/
• 376 Burris HA, Moore MJ, Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413 https://www.ncbi.nlm.nih.gov/pubmed/9196156
• 377 Sohal DPS, Mangu PB, Khorana AA. et al. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 2016; 34: 2784-2796 https://pubmed.ncbi.nlm.nih.gov/27247222/
• 378 Conroy T, Desseigne F, Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825 https://www.ncbi.nlm.nih.gov/pubmed/21561347
• 379 Moore MJ, Goldstein D, Hamm J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2007; 25: 1960-1966 https://pubmed.ncbi.nlm.nih.gov/17452677/
• 380 Von Hoff DD, Ervin T, Arena FP. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine 2013; 369: 1691-1703 https://pubmed.ncbi.nlm.nih.gov/24131140/
• 381 Sohal DPS, Kennedy EB, Khorana A. et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology 2018; 36: 2545-2556 https://pubmed.ncbi.nlm.nih.gov/29791286/
• 382 Poplin E, Feng Y, Berlin J. et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27: 3778-3785 https://pubmed.ncbi.nlm.nih.gov/19581537/
• 383 National Institute for H, Care E. Pancreatic cancer in adults: diagnosis and management NICE Guideline NG85. 2018 https://www.nice.org.uk/guidance/ng85
• 384 Tu C, Zheng F, Wang JY. et al. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?. Asian Pacific journal of cancer prevention : APJCP 2015; 16: 5681-5686 https://pubmed.ncbi.nlm.nih.gov/26320435/
• 385 Li Q, Yan H, Liu W. et al. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomized controlled trials. PLoS ONE 2014; 9: e104346 https://pubmed.ncbi.nlm.nih.gov/25093849/
• 386 Chin V, Nagrial A, Sjoquist K. et al. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 2018; 3: CD011044 https://www.ncbi.nlm.nih.gov/pubmed/29557103
• 387 Heinemann V, Vehling-Kaiser U, Waldschmidt D. et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013; 62: 751-759 https://pubmed.ncbi.nlm.nih.gov/22773551/
• 388 Van Cutsem E, Vervenne WL, Bennouna J. et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of Clinical Oncology 2009; 27: 2231-2237 https://pubmed.ncbi.nlm.nih.gov/19307500/
• 389 Eltawil KM, Renfrew PD, Molinari M. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB (Oxford) 2012; 14: 260-268 https://www.ncbi.nlm.nih.gov/pubmed/22404265
• 390 Ciliberto D, Botta C, Correale P. et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013; 49: 593-603 https://www.ncbi.nlm.nih.gov/pubmed/22989511
• 391 Tong M, Wang J, Zhang H. et al. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: A systematic review and meta-analysis of clinical randomized phase III trials. Journal of Cancer 2019; 10: 968-978 https://pubmed.ncbi.nlm.nih.gov/30854103/
• 392 O'Reilly EM, Lee JW, Zalupski M. et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol 2020; 38: 1378-1388 https://www.ncbi.nlm.nih.gov/pubmed/31976786
• 393 Park W, Chen J, Chou J. et al. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research 2020; 26: 3239-3247 https://pubmed.ncbi.nlm.nih.gov/32444418/
• 394 Golan T, Hammel P, Reni M. et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 2019; 381: 317-327 https://www.ncbi.nlm.nih.gov/pubmed/31157963
• 395 Herman JM, Chang DT, Goodman KA. et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer (0008543X) 2015; 121: 1128-1137 https://pubmed.ncbi.nlm.nih.gov/25538019/
• 396 Zhu CP, Shi J, Chen YX. et al. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol 2011; 99: 108-113 https://pubmed.ncbi.nlm.nih.gov/21571383/
• 397 Hurt CN, Falk S, Crosby T. et al. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. Br J Cancer 2017; 116: 1264-1270 https://pubmed.ncbi.nlm.nih.gov/28376080/
• 398 Ambe C, Fulp W, Springett G. et al. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. J Gastrointest Cancer 2015; 46: 284-290 https://www.ncbi.nlm.nih.gov/pubmed/26018826
• 399 Muscaritoli M, Arends J, Bachmann P. et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr 2021; 40 (05) 2898-2913 https://pubmed.ncbi.nlm.nih.gov/33946039/
• 400 Arends J, Bachmann P, Baracos V. et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36 (01) 11-48 https://pubmed.ncbi.nlm.nih.gov/27637832/
• 401 Roeland E, Bohlke K, Baracos V. et al. Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol 2020; 38 (21) 2438-2453 https://pubmed.ncbi.nlm.nih.gov/32432946/
• 402 Moss AC, Morris E, Mac MathunaP. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev 2006; CD004200 https://pubmed.ncbi.nlm.nih.gov/16437477/
• 403 Hausegger KA, Thurnher S, Bodendorfer G. et al. Treatment of malignant biliary obstruction with polyurethane-covered Wallstents. Am J Roentgenol 1998; 170: 403-408 https://pubmed.ncbi.nlm.nih.gov/9456954/
• 404 Isayama H, Komatsu Y, Tsujino T. et al. A prospective randomised study of “covered” versus “uncovered” diamond stents for the management of distal malignant biliary obstruction. Gut 2004; 53: 729-734 https://pubmed.ncbi.nlm.nih.gov/15082593/
• 405 Speer AG, Cotton PB, Russell RC. et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2: 57-62 https://pubmed.ncbi.nlm.nih.gov/2439854/
• 406 Aranha GV, Prinz RA, Greenlee HB. Biliary enteric bypass for benign and malignant disease. Am Surg 1987; 53: 403-406 https://pubmed.ncbi.nlm.nih.gov/3605859/
• 407 DiFronzo LA, Egrari S, O'Connell TX. Choledochoduodenostomy for palliation in unresectable pancreatic cancer. Arch Surg 1998; 133: 820-825 https://pubmed.ncbi.nlm.nih.gov/9711954/
• 408 Urbach DR, Bell CM, Swanstrom LL. et al. Cohort study of surgical bypass to the gallbladder or bile duct for the palliation of jaundice due to pancreatic cancer. Ann Surg 2003; 237: 86-93 https://pubmed.ncbi.nlm.nih.gov/12496534/
• 409 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft) DK. Entwicklung von leitlinienbasierten Qualitätsindikatoren Methodenpapier für das Leitlinienprogramm Onkologie, Version 21. 2017 http://www.leitlinienprogramm-onkologie.de/methodik/informationen-zur-methodik/
• 410 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – Ständige Kommission L. AWMF-Regelwerk „Leitlinien“, 2 Auflage. 2020 https://www.awmf.org/regelwerk/